- Previous Close
2.6250 - Open
2.6600 - Bid --
- Ask --
- Day's Range
2.5150 - 2.7500 - 52 Week Range
1.5200 - 5.9600 - Volume
203,518 - Avg. Volume
53,672 - Market Cap (intraday)
111.547M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2300 - Earnings Date Sep 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.20
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
www.crossject.comRecent News: ALCJ.PA
View More
Performance Overview: ALCJ.PA
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALCJ.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALCJ.PA
View MoreValuation Measures
Market Cap
108.02M
Enterprise Value
124.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
690.83
Price/Book (mrq)
--
Enterprise Value/Revenue
859.57
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.34%
Return on Equity (ttm)
--
Revenue (ttm)
2.5M
Net Income Avi to Common (ttm)
-10.48M
Diluted EPS (ttm)
-0.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
5.95M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: ALCJ.PA
View MoreCompany Insights: ALCJ.PA
ALCJ.PA does not have Company Insights